Summary
Biogen Inc.'s 2017 10-K filing highlights a year of strategic repositioning and continued growth, particularly driven by its Multiple Sclerosis (MS) franchise and the promising launch of SPINRAZA for Spinal Muscular Atrophy (SMA). The company reported total revenues of $12.27 billion, a 7.2% increase over 2016, with product revenues reaching $10.35 billion, up 5.5%. This growth was supported by strong performances from TECFIDERA and TYSABRI within the MS segment, and the significant ramp-up of SPINRAZA sales, which began commercialization in late 2016. The company also saw a notable 18.6% increase in revenues from its anti-CD20 therapeutic programs, largely due to royalty income from OCREVUS and its share of profits from RITUXAN. Key strategic initiatives for 2017 included optimizing the MS business, accelerating efforts in SMA, expanding its neuroscience pipeline, and creating a leaner operating model. The company also addressed significant legal matters, including a settlement with Forward Pharma related to TECFIDERA, and began the process of implementing the 2017 Tax Act, which included a substantial charge for the Transition Toll Tax. Biogen continued to invest in its pipeline through acquisitions and licensing agreements, particularly focusing on Alzheimer's disease and other neurodegenerative disorders, signaling a commitment to future growth beyond its established franchises.
Financial Highlights
55 data points| Revenue | $12.27B |
| Cost of Revenue | $1.63B |
| Gross Profit | $10.64B |
| SG&A Expenses | $1.93B |
| Operating Expenses | $6.93B |
| Operating Income | $5.35B |
| Interest Expense | $250.80M |
| Net Income | $2.54B |
| EPS (Basic) | $11.94 |
| EPS (Diluted) | $11.92 |
| Shares Outstanding (Basic) | 212.60M |
| Shares Outstanding (Diluted) | 213.00M |
Key Highlights
- 1Total revenues increased by 7.2% to $12.27 billion in 2017, driven by strong performance in key therapeutic areas.
- 2Product revenues grew by 5.5% to $10.35 billion, primarily fueled by TECFIDERA, SPINRAZA, and anti-CD20 therapies.
- 3SPINRAZA, a treatment for Spinal Muscular Atrophy (SMA), showed significant early commercial success and contributed substantially to revenue growth.
- 4The company implemented a corporate restructuring program to streamline operations and reallocate resources towards prioritized research and development and value creation opportunities.
- 5Biogen settled a significant legal dispute with Forward Pharma related to TECFIDERA intellectual property for $1.25 billion.
- 6The company recorded a substantial charge of $1,173.6 million related to the 2017 Tax Act, including a $989.6 million expense for the Transition Toll Tax.
- 7Biogen continued to invest in its pipeline through strategic collaborations and acquisitions, notably in Alzheimer's disease and other neurodegenerative conditions.